Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1

Interventions

tusamitamab ravtansine 2Gemcitabine 2pembrolizumab 1necitumumab 1Ramucirumab 1MLN 8237 1LY3023414 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Non-small Cell Lung Cancer Metastatic × MLN 8237 × Clear all
NCT01471964 2018-05-17

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
22 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡